|
| Press Releases |
|
 |
|
| Wednesday, August 29, 2018 |
|
|
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab |
| Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension (LTE) Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. more info >> |
|
| Tuesday, August 28, 2018 |
|
|
Eisai: Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ |
| The average change in weight from baseline was -4.2 kg with BELVIQ and -1.4 kg with placebo, translating to a 2.8 kg greater net weight loss with BELVIQ (nominal p-value<0.001). more info >> |
|
| Thursday, August 23, 2018 |
|
|
Eisai: European Commission Grants Marketing Authorization for LENVIMA (Lenvatinib) |
| This is the first new first-line treatment option for advanced or unresectable HCC to be approved in Europe in approximately 10 years. more info >> |
|
| Tuesday, July 31, 2018 |
|
|
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech |
| Under this agreement, Eisai will supply CYB with lorcaserin. Eisai will receive a one-time contractual payment and milestone payments dependent upon acquisition of regulatory approval. more info >> |
|
|
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA |
| The LENVIMA/KEYTRUDA combination therapy is being jointly developed by Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. as part of the strategic collaboration announced in March 2018. more info >> |
|
| Thursday, July 26, 2018 |
|
|
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018 |
| Eisai Co., Ltd. and Biogen Inc. announced detailed results from the Phase II study (Study 201) with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease as part of Session DT-01 "Recent Developments in Therapeutics" at AAIC 2018 being held in Chicago, Illinois, United States on July 25. more info >> |
|
|
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018 |
| Eisai Co., Ltd. and Biogen Inc. announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE inhibitor elenbecestat (development code: E2609) at the AAIC 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. more info >> |
|
| Thursday, July 19, 2018 |
|
|
Latest Data on Eisai's Alzheimer's Disease / Dementia Pipeline to be Presented at Alzheimer's Association International Conference (AAIC) 2018 |
| Eisai Co., Ltd. announces today that a total of 13 presentations highlighting results from a Phase II clinical study (Study 201) of the anti-amyloid beta (Abeta) protofibril antibody BAN2401 and a Phase II clinical study (Study 202) will be given at the Alzheimer's Association International Conference (AAIC) 2018, in Chicago. more info >> |
|
| Wednesday, July 18, 2018 |
|
|
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ |
| This study was conducted at over 400 sites in eight countries including the United States in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and is the largest cardiovascular outcome trial conducted to date for a weight loss medication. more info >> |
|
| Wednesday, July 11, 2018 |
|
|
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan |
| Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. will launch the oral antifungal agent NAILIN Capsules 100mg in Japan on July 27, 2018. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Champion REIT Presents 'Lupus Reimagined' Art Exhibition, Connecting Community Through Art 
Jun 6, 2025 22:35 HKT/SGT
|
|
|
International Consortium Rolls Out Major EV Battery Swapping Initiative in Tokyo
Jun 6, 2025 16:42 JST
|
|
|
Tredu.com Launches Global Platform to Revolutionize Trading Education
Jun 6, 2025 15:40 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Receives 2025 Technology Award from Catalyst Manufacturers Association, Japan, for Development and Practical Application of Electrode Catalysts for PEM Water Electrolysis
Jun 6, 2025 11:00 JST
|
|
|
Fujitsu unveils Technology and Service Vision 2025: People-AI collaboration for a net positive future
Jun 6, 2025 10:44 JST
|
|
|
Latest Firewall Vulnerability Reinforces Need for Post-Breach Privileged Access Controls - TACACS.net Offers a Critical Layer
Jun 6, 2025 04:30 HKT/SGT
|
|
|
Naoris Protocol Expands into the Nordics with Strategic Consulting Hub in Oslo
Jun 5, 2025 21:00 HKT/SGT
|
|
|
PlayX Showcases AI-Powered Transparency and Fairness at SiGMA Asia 2025 in Manila
Jun 5, 2025 17:00 HKT/SGT
|
|
|
The Generation Essentials Group and Black Spade Acquisition II Co Complete Business Combination
Jun 5, 2025 11:33 HKT/SGT
|
|
|
Global Communities Unite at centralwOrld as Thailand Steps Forward on Global LGBTQ+ Stage with Central Pattana's Pride For All
Jun 5, 2025 08:30 HKT/SGT
|
|
|
TF International Facilitates Hong Kong's Successful Issuance of First Central Asian Sovereign Bond
Jun 4, 2025 22:28 HKT/SGT
|
|
|
Alpha Growth plc: Alpha Alternative Assets Fund Update ("AAAF")
Jun 4, 2025 15:00 JST
|
|
|
MHI Thermal Systems Receives A' Design Awards
Jun 4, 2025 14:10 JST
|
|
|
CBL International Limited Announces Share Repurchase Program
Jun 4, 2025 12:00 HKT/SGT
|
|
|
Orange completes successful trial of Fujitsu 1FINITY optical transport solution
Jun 4, 2025 12:58 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
